Your browser doesn't support javascript.
loading
Long versus short course anti-microbial therapy of uncomplicated Staphylococcus aureus bacteraemia: a systematic review.
Schnizer, Martin; Schellong, Paul; Rose, Norman; Fleischmann-Struzek, Carolin; Hagel, Stefan; Abbas, Mohamed; Payne, Brendan; Evans, Rebecca N; Pletz, Mathias W; Weis, Sebastian.
Afiliação
  • Schnizer M; Institute for Infectious Disease and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.
  • Schellong P; Institute for Infectious Disease and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.
  • Rose N; Institute for Infectious Disease and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.
  • Fleischmann-Struzek C; Institute for Infectious Disease and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.
  • Hagel S; Institute for Infectious Disease and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.
  • Abbas M; Infection Control Program and WHO Collaborating Center on AMR and IPC, University of Geneva Hospitals and Faculty of Medicine, Service of Infectious Diseases, Geneva, Switzerland; MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, L
  • Payne B; Translational and Clinical Research Institute, Newcastle University, Newcastle-Upon-Tyne, UK; Department of Infection and Tropical Medicine, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
  • Evans RN; Bristol Trials Centre, University of Bristol, Bristol, UK.
  • Pletz MW; Institute for Infectious Disease and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.
  • Weis S; Institute for Infectious Disease and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany; Leibniz Institute for Natural Product Research and Infection Biology, Hans-Knöll Institute, Jena, Germany. Electronic address: Sebastian.weis@med.uni-jena.de.
Clin Microbiol Infect ; 30(10): 1254-1260, 2024 Oct.
Article em En | MEDLINE | ID: mdl-38823452
ABSTRACT

BACKGROUND:

Current guidelines recommend at least 2 weeks duration of antibiotic therapy (DOT) for patients with uncomplicated Staphylococcus aureus bacteraemia (SAB) but the evidence for this recommendation is unclear.

OBJECTIVES:

To perform a systematic literature review assessing current evidence for recommended DOT for patients with SAB.

METHODS:

The following are the methods used for this study. DATA SOURCES We searched MEDLINE, ISI Web of Science, the Cochrane Database and clinicaltrials.gov from inception to March 30, 2024. References of eligible studies were screened and experts in the field contacted for additional articles. STUDY ELIGIBILITY CRITERIA All clinical studies, regardless of design, publication status and language.

PARTICIPANTS:

Adult patients with uncomplicated SAB.

INTERVENTIONS:

Long (>14 days; >18 days; 11-16 days) vs. short (≤14 days; 10-18 days; 6-10 days, respectively) DOT with the DOT being defined as the first until the last day of antibiotic therapy. ASSESSMENT OF RISK OF BIAS Risk of bias was assessed using the ROBINS-I-tool. METHODS OF DATA

SYNTHESIS:

The primary outcome was 90-day all-cause mortality. Only studies presenting results of adjusted analyses for mortality were included. Data synthesis could not be performed.

RESULTS:

Eleven nonrandomized studies were identified that fulfilled the pre-defined inclusion criteria, of which three studies reported adjusted effect ratios. Only these were included in the final analysis. We did not find any RCT. Two studies with 1230 patients reported the primary endpoint 90-day all-cause mortality. Neither found a statistically significant superiority for longer (>14 days; 11-16 days) or shorter DOT (≤14 days; 6-10 days, respectively) for patients with uncomplicated SAB. Two studies investigated the secondary endpoint 30-day all-cause mortality (>18 days; 11-16 days vs. 10-18 days; 6-10 days, respectively) and did not find a statistically significant difference. All included studies had a moderate risk of bias.

CONCLUSIONS:

Sound evidence that supports any duration of antibiotic treatment for patients with uncomplicated SAB is lacking.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Estafilocócicas / Staphylococcus aureus / Bacteriemia / Antibacterianos Limite: Humans Idioma: En Revista: Clin Microbiol Infect Assunto da revista: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Estafilocócicas / Staphylococcus aureus / Bacteriemia / Antibacterianos Limite: Humans Idioma: En Revista: Clin Microbiol Infect Assunto da revista: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha